Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This study evaluates the cost-effectiveness of tirzepatide (TZP) 10 and 15 mg once weekly (QW) compared to placebo among individuals with type 2 diabetes (T2D) and comorbid obesity in the United States (US).
Research Design And Methods: The Building, Relating, Assessing and Validating Outcomes (BRAVO) Diabetes Model was used to assess the cost-effectiveness of the two TZP doses in individuals with T2D and comorbid obesity from the US healthcare perspective, using a 30-year time horizon. Treatment effects were derived from the SURMOUNT-2 trial and assumed to persist for 5 years. Cost estimates were based on trial data and medication prices from GoodRx. Health utilities for diabetes-related complications were obtained from existing literature. One-way sensitivity analysis and probability sensitivity analysis (PSA) were conducted to examine the robustness. The willingness-to-pay (WTP) threshold was set at $100 000 per quality-adjusted life year (QALY) gained.
Results: Compared with placebo, TZP 15 mg QW gained 0.69 QALYs, 0.58 life-years and a cost saving of $1409. TZP 10 mg QW gained 0.60 QALYs, 0.49 life-years and increased costs by $1855, resulting in an incremental cost-effectiveness ratio (ICERs) of $3092 per QALY. Sensitivity analysis confirmed the robustness of results. The probability of cost-effectiveness was 98.9% for TZP 15 mg QW and 98.9% for TZP 10 mg QW had 98.5%.
Conclusion: Compared with placebo, both TZP 15 mg and 10 mg QW are cost-effective options for individuals with T2D and comorbid obesity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.16466 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
The Role of Artificial Intelligence in Cardio-Obstetrics - Current Applications and Future Directions.
Trends Cardiovasc Med
September 2025
Department of Cardiology, NYU Langone Health and NYU School of Medicine, New York, NY.
Cardio-obstetrics is a growing sub-specialty focused on the prevention, diagnosis, and management of high-risk pregnancies in women with cardiac disease, a condition affecting 1-4% of pregnancies and a leading cause of indirect maternal mortality in developed countries. The prevalence of maternal cardiac disease is rising due to factors such as increasing maternal age, obesity, comorbidities, and improved survival of individuals with congenital heart disease. Artificial intelligence (AI) is increasingly used in cardiology to enhance early diagnosis, risk stratification, and treatment planning, offering promising tools to support the diagnostic and therapeutic complexities of maternal cardiac disease.
View Article and Find Full Text PDFThromboembolic risks after knee arthroplasty in patients with severe obesity: A large-scale analysis using Japanese medical claims data.
J Orthop Sci
September 2025
Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-Ku, Sendai, Miyagi 980-8574, Japan. Electronic address:
Background: Obesity is associated with an increased risk of complications after total knee arthroplasty (TKA) and unicompartmental knee arthroplasty (UKA), particularly in Western populations. However, the effect of severe obesity (body mass index [BMI] ≥ 35 kg/m) on postoperative complications in Japanese patients remains unclear.
Methods: We conducted a retrospective cohort study using Japan's Diagnosis Procedure Combination (DPC) database, including patients who underwent TKA or UKA between April 2016 and March 2023.
Adults With Congenital Heart Disease Have an Increased Prevalence of Autoimmunity.
JACC Adv
September 2025
Section of Cardiovascular Medicine, Departments of Pediatrics and Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address:
Background: Adult congenital heart disease (ACHD) individuals have increased risk of noncardiac comorbidities including cancer and infections. Whether they are at increased risk of autoimmunity is unknown.
Objectives: The purpose of this study was to understand the association of ACHD and risk for autoimmunity.
European survey on metabolic and cardiovascular risk in Cushing syndrome.
J Endocrinol Invest
September 2025
Department of Medicine-DIMED, University of Padova, Padova, Italy.
Background: Cushing's syndrome (CS) is associated with increased metabolic and cardiovascular (CV) risk factors and morbidities. Evidence-based guidelines for the management of these issues in active or remitted CS are not available, so best practice is derived from guidelines developed for the general population. We aimed to evaluate the awareness and practice variation for CV comorbidities of CS across Reference Centres (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
View Article and Find Full Text PDF